Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOPI study for selecting the best HRD test in ovarian cancer patients receiving PARP inhibitor maintenance
NL-OMON56928Terminated
- Sponsor
- Erasmus MC
- Start
- Aug 2024
- Countries
- 1
01
Overview
Open-label trial in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 1 more (4 arms), sponsored by Erasmus MC. Primary endpoint: Progression-free survival. Started Aug 2024; status: terminated.
02
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)ovarian cancer
Beyond the preview
Go deeper on NL-OMON56928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56928.